Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Truxima and Ruxience are considered as therapeutically equivalent to Rituxan for FDA approved indications. As Truxima and Ruxience receives additional approvals for traditional rituximab indications, the 3 drugs will be considered interchangeable for these uses also. The most cost effective product will be used in a specific setting, time period, or patient case.
For non-oncologic indications including, but not limited to, rheumatology, nephrology, and benign hematology, a second clinical verification by the Oncology Clinical Specialists is not required. These orders can be verified by the covering pharmacist as clinically appropriate. For more information: Rituximab for Non-Malignant Indications
Outpatient riTUXimab cycle 2+ rapid infusion protocol available for adults.
Add Formweb to your mobile device
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Truxima and Ruxience are considered as therapeutically equivalent to Rituxan for FDA approved indications. As Truxima and Ruxience receives additional approvals for traditional rituximab indications, the 3 drugs will be considered interchangeable for these uses also. The most cost effective product will be used in a specific setting, time period, or patient case.
For non-oncologic indications including, but not limited to, rheumatology, nephrology, and benign hematology, a second clinical verification by the Oncology Clinical Specialists is not required. These orders can be verified by the covering pharmacist as clinically appropriate. For more information: Rituximab for Non-Malignant Indications
Outpatient riTUXimab cycle 2+ rapid infusion protocol available for adults.
RiTUXimab cycle 2+ rapid infusion (adults)
Reviewed: 23 July 2019 (Truxima). October 22, 2019, 24 March 2020 (Ruxience)